Shared on30 Jul 25Fair value Decreased 30%
The sharp reduction in Puma Biotechnology’s price target is primarily driven by a marked shift from modest expected revenue growth to anticipated revenue contraction, with valuation multiples increasing accordingly, resulting in a new consensus target of $3.00 (down from $4.29). What's in the News Dropped from multiple Russell growth and small-cap indices, including Russell 2000, 2500, 3000, Microcap, and Small Cap Comp Growth benchmarks.
Shared on01 May 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on23 Apr 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on17 Apr 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on09 Apr 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on02 Apr 25Fair value Increased 0.70%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on26 Mar 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on19 Mar 25Fair value Decreased 0.70%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on11 Mar 25Fair value Increased 11%
AnalystConsensusTarget has increased revenue growth from -5.3% to -0.7%, decreased profit margin from 15.2% to 7.5%, increased future PE multiple from 8.8x to 16.7x and decreased discount rate from 7.7% to 6.7%.